Chimerix Stock

Chimerix Current Liabilities

Delisted·Apr 17, 2025

The Current Liabilities of Chimerix (CMRX) as of Aug 26, 2026 is 43.80 M USD. In the previous year, Current Liabilities was 34.88 M USD — a change of 25.60% (higher).

Current Liabilities

43.80 MUSD

YoY

25.60%

Last updated:

Current Liabilities of Chimerix is 2026 43.80 M USD. Current Liabilities of Chimerix was 2025 34.88 M USD. It decreases by 25.60% higher compared to the previous year.

The Chimerix Current Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Liabilities
Date
Current Liabilities
Jan 1, 2017
22.82 M USD
Jan 1, 2018
21.27 M USD
Jan 1, 2019
16.68 M USD
Jan 1, 2020
15.95 M USD
Jan 1, 2021
43.00 M USD
Jan 1, 2022
38.59 M USD
Jan 1, 2023
34.88 M USD
Jan 1, 2024
43.80 M USD
The Chimerix Current Liabilities history
YEARCurrent LiabilitiesYoY
43.80 MUSD+25.60%
34.88 MUSD-9.62%
38.59 MUSD-10.25%
43.00 MUSD+169.65%
15.95 MUSD-4.43%
16.68 MUSD-21.55%
21.27 MUSD-6.81%
22.82 MUSD+36.27%
16.75 MUSD-44.61%
30.23 MUSD+20.34%
25.12 MUSD+37.98%
18.21 MUSD+36.66%
13.32 MUSD+40.04%
9.51 MUSD
0.00USD
Access this data via the Eulerpool API

Chimerix Stock analysis

What does Chimerix do? Chimerix Inc is a biopharmaceutical company focused on the development of antiviral drugs. The company was founded in 2002 and is headquartered in Durham, North Carolina. The history of Chimerix dates back to the research of Dr. George Painter, a renowned scientist in the field of antiviral therapy. He discovered that a certain group of molecules, known as nucleoside analogues, have antiviral properties. The idea was to use these molecules as a starting point for the development of drugs that specifically target viruses. The core idea of Chimerix was to create a new business model that is different from traditional pharmaceutical companies. Instead of focusing on the lengthy and costly development of new compounds, the company wanted to utilize existing molecules and create new drugs through targeted modifications. This approach was not only expected to be faster and cost-effective but also to offer higher chances of success. Chimerix is divided into several business segments. The most important segment is antiviral therapy, where the company focuses on developing drugs against various viruses such as Cytomegalovirus (CMV), Adenovirus, and Herpesvirus. Another business segment of Chimerix is oncology. Here, the company also relies on modifying existing compounds to develop new and effective cancer drugs. One promising molecule currently being developed is Brincidofovir, which not only has antiviral properties but also possesses antitumor properties. In addition to drug development, Chimerix also offers support for clinical trials. The company collaborates with various research institutions and biopharmaceutical companies to test the efficacy and safety of new compounds. The most well-known product of Chimerix is Brincidofovir. This antiviral drug is currently being tested in clinical trials and has the potential to be used against a range of viruses. Its use is particularly promising in patients undergoing immunosuppressive therapy, such as those after a stem cell transplant. Chimerix aims to develop innovative and effective drugs that help patients overcome serious diseases. With its unique business model and close collaboration with the research community, the company has already made promising progress and is an important player in the field of antiviral therapy and oncology. Chimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Chimerix stock

Current Liabilities of Chimerix is 43.80 M USD in 2026.

Current Liabilities of Chimerix changed from 34.88 M USD to 43.80 M USD, representing a 25.60% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Liabilities Chimerix since 2006 – with annual values, charts, and detailed analysis.

Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.

Current Liabilities's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Chimerix historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Chimerix

All Key Metrics — Chimerix